Form 483

Lilly del Caribe, Inc Form 483, 2013-07-22

FDA issued a Form 483 to Lilly del Caribe, Inc on 2013-07-22 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Lilly del Caribe, Inc · Carolina, United States · Issued July 22, 2013

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

22 Jul 2013
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Libia M Lugo, Raquel Gonzalez Rivera

22 Jul 2013
21 CFR 211.192

Extent of discrepancy, failure investigations

Cited by Libia M Lugo, Raquel Gonzalez Rivera

22 Jul 2013
21 CFR 212.30(a)

Prevention of contamination

Cited by Libia M Lugo, Raquel Gonzalez Rivera

22 Jul 2013
21 CFR 314.81(b)(1)(ii)

Contamination, chemical or physical change, deterioration

Cited by Libia M Lugo, Raquel Gonzalez Rivera

Inspected site

LDLilly del Caribe, IncCarolina, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 212.30(a)Cited across public-safe Form 483 observations1x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 4 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere